 |
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2015, vol. 21, issue 4
Subject Area: Medicine - Urology
Pages: 926-940
DOI: 10.5272/jimab.2015214.926
Published online: 16 November 2015
J of IMAB 2015 Oct-Dec;21(4):926-940
CANCER IMMUNOLOGY AND IMMUNOTHERAPY – UNDERSTANDING AND ADAPTATION THE CURRENT EVIDENCE TO OPTIMIZE PATIENT THERAPY OUTCOMES.
Orlin Savov1
, Vladimir Mladenov2, Mitko Tzvetkov3, Dimitar Mladenov2,
1) Urology practice, Department of Urology “St. Theresia Hospital”, Nuremberg, Germany.
2) Clinic Urology, University Hospital Alexandrovska, Medical University Sofia, Bulgaria.
3) Clinic Urology, Fifth City Hospital Sofia, Bulgaria.
ABSTRACT:
The aim of this publication includes the try to act as intermediary to the readers, which should be able to understand:
- The description of the cancer immunotherapy mechanisms in the context of current therapy decisions for the treatment of cancer
- The including criteria for those patients with cancer who could be appropriate candidates for immunotherapy
- And to optimize patient outcomes by using best practices to manage the adverse events associated with immunotherapy treatment
More than 15 promising immunotherapy approaches being tested in clinical trials with appropriate patients and colleagues for enrollment and peer-to-peer education purposes, respectively.
Key words: cancer immunotherapy mechanisms,
- Download FULL TEXT /PDF 595 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Savov O, Mladenov V, Tzvetkov M, Mladenov D. Cancer immunology and immunotherapy – understanding and adaptation the current evidence to optimize patient therapy outcomes. J of IMAB. 2015 Oct-Dec;21(4):926-940. doi: http://dx.doi.org/10.5272/jimab.2015214.926
Correspondence to: Dr Orlin Savov, Urology practice, Department of Urology “St. Theresia Hospital”; 24, Mommsenstrasse Str., 90491 Nuremberg, Germany; E-mail: osavov@aol.com
REFERENCES:
1. Drake CG, Lipson EJ, Brahmer, JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014 Jan;11(1):24-37. [PubMed] [CrossRef]
2. Medzhitov R, Janeway C Jr. Innate immune recognition: mechanisms and pathways. Immunol Rev. 2000 Feb;173:89-97. [PubMed] [CrossRef]
3. Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nat Rev Immunol. 2013 May;13(5):309-320. [PubMed] [CrossRef]
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul;363[5]:411-422. [PubMed] [CrossRef]
5. Vansteenkiste J, Cho B, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. MAGRIT, a double-blind, randomized, placebocontrolled phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC). Program and abstracts from the 2014 ESMO. Abstract 1173O.
6. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun;364(26):2517-2526. [PubMed] [CrossRef]
7. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug;363(8):711-723. [PubMed] [CrossRef]
8. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013 Jan;19(2):462-468. [PubMed] [CrossRef]
9. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007 Nov-Dec;30(8):825-830. [PubMed] [CrossRef]
10. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012 Jun;30(17):2046-2054. [PubMed] [CrossRef]
11. ClinicalTrials.gov. Randomized, multicenter, double-blind, phase 3 trial comparing the efficacy of ipilimumab in addition to paclitaxel and carboplatin versus placebo in addition to paclitaxel and carboplatin in subjects with stage IV/recurrent non small cell lung cancer (NSCLC). Available at: http://clinicaltrials.gov/ct2/show/NCT01285609
12. ClinicalTrials.gov. Randomized, multicenter, double-blind, phase 3 trial comparing the efficacy of ipilimumab plus etoposide/platinum versus etoposide/platinum in subjects with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC). Available at: http://clinicaltrials.gov/ct2/show/NCT01450761
13. ClinicalTrials.gov. Randomized, double-blind, phase 3 trial to compare the efficacy of ipilimumab vs placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapynaive castration resistant prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01057810
14. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J ClinOncol. 2010 Jul;28(19):3167-3175. [PubMed] [CrossRef]
15. Topalian SL, Sznol M, Brahmer JR, McDermott DF, Smith DC, Gettinger SN, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: survival and long-term safety in a phase I trial. Program and abstracts from the 2013 ASCO, Abstract 3002.
16. Rizvi NA, Antonia SJ, Chow LQ, Brahmer JR, Juergens RA, Borghaei H, et al. A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive nonsmall cell lung cancer (NSCLC) patients (pts). Program and abstracts from the 2013 ASCO, Abstract 8072.
17. ClinicalTrials.gov. An open-label randomized phase III trial of BMS-936558 (nivolumab) versusdocetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer(NSCLC). Available at: http://clinicaltrials.gov/ct2/show/NCT01642004
18. ClinicalTrials.gov. An open-label randomized phase III Trial of BMS-936558 (nivolumab) versusdocetaxel in previously treated metastatic non-squamous non-small cell lung cancer (NSCLC).Available at: http://clinicaltrials.gov/ct2/show/NCT01673867 .
19. Sznol M, Kluger HM, Hodi S, et al. Survival and long-term follow-up of safety and response inpatients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). Program and abstracts from the 2013 ASCO, Abstract CRA9006
20. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) inmelanoma. N Engl J Med. 2013; 369:134-144. [CrossRef]
21. Drake CG, McDermott DF, Sznol M, et al. Survival, safety and response duration results ofnivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previouslytreated metastatic renal cell carcinoma (mRCC): long-term patient follow-up. Program andabstracts from the 2013 ASCO, Abstract 4514.
22. ClinicalTrials.gov. A randomized, blinded, phase 2 dose-ranging study of BMS-936558 (MDX-1106) in subjects with progressive, advanced/metastatic clear-cell renal cell carcinoma who havereceived prior anti-angiogenic therapy. 2015; Available at: http://clinicaltrials.gov/ct2/show/NCT01354431
23. ClinicalTrials.gov. An exploratory study to investigate the immunomodulatory activity of variousdose levels of anti programmed-death-1 (PD-1) antibody (BMS-936558) in subjects withmetastatic clear cell renal cell carcinoma (RCC). Available at: http://clinicaltrials.gov/ct2/show/NCT01358721
24. Clinical Trials.gov. A phase 1 study of nivolumab (BMS-936558) plus sunitinib, pazopanib oripilimumab in subjects with metastatic renal cell carcinoma. 2014;
Available at: http://clinicaltrials.gov/ct2/show/NCT01472081
25. ClinicalTrials.gov. A randomized, open-label, phase 3 study of nivolumab (BMS-936558) vseverolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who havereceived prior anti-angiogenic therapy. Available at:http://clinicaltrials.gov/ct2/show/NCT01668784.
26. Brahmer JR, Tykodi SS, Chow LQ, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patientswith advanced cancer. N Engl J Med. 2012; 366(26):2455-2465. [PubMed] [CrossRef]
27. Herbst RS, Gordon MS, Fine GD, et al. A study of MPDL3280A, an engineered PD-L1 antibody inpatients with locally advanced or metastatic tumors. Program and abstracts from the 2013 ASCO, Abstract 3000.
28. Segal NH, Antonia SJ, Brahmer JR, et al. Preliminary data from a multi-arm expansion study ofMEDI4736, an anti-PD-L1 antibody. Program and abstracts from the 2014 ASCO, Abstract 3002.
29. Amin A, Plimack ER, Infante JR, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) incombination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma(mRCC). Program and abstracts from the 2014 ASCO. Abstract 5010.
30. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013 Jul;369(2):122-133. [PubMed] [CrossRef]
31. Sznol M, Kluger HM, Callahan MK, et al. Survival, response duration, and activity by BRAFmutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab(IPI) concurrent therapy in advanced melanoma (MEL). Program and abstracts from the 2014 ASCO, Abstract LBA9003.
32. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012 Feb 15;72(4):917-27. [PubMed] [CrossRef]
33. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 andPD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010 Sep 27;207(10):2187-2194. [PubMed] [CrossRef]
34. McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer. 2009 May 15;115(10 Suppl):2298-2305. [PubMed] [CrossRef]
35. Brahmer JR, Horn L, Gandhi L, et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients(pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroupanalysis. Program and abstracts from the 2014 ASCO, Abstract 8112.
36. Rizvi NA, Garon EB, Patnaik A, et al. Safety and clinical activity of MK-3475 as initial therapy inpatients with advanced non-small cell lung cancer (NSCLC). Program and abstracts from the 2014 ASCO, Abstract 8007.
37. Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of MK-3475 in previously treatedpatients (pts) with non-small cell lung cancer (NSCLC). ASCO, Abstract 8020.
38. Soria JC, Cruz C, Bahleda R, et al. Clinical activity, safety and biomarkers of PD-L1 blockade innon-small cell lung cancer (NSCLC). Program and abstracts from the 2013 European CancerCongress, Abstract 3408.
39. Powles T, Vogelzang NJ, Fine GD, et al. Inhibition of PD-L1 by MPDL3280A and clinical activityin pts with metastatic urothelial bladder cancer (UBC). 2014 ASCO, Abstract 5011.
40. Seiwert TY, Burtness B, Weiss J, et al. A phase Ib study of MK-3475 in patients with humanpapillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer.Program and abstracts from the 2014 ASCO; Abstract 6011.
41. Muro K, Bang Y, Shankiaran V, et al. A phase 1b study of pembrolizumab (Pembro; MK-3475) inpatients (Pts) with advanced gastric cancer. Program and abstracts from the 2014 ESMO.Abstract LBA15.
42. Rizvi N, Chow LQ, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant(EGFR MT) advanced NSCLC. Program and abstracts from the 2014 ESMO, Abstract 8022.
43. Gettinger SN, Shepherd FA, Antonia SJ, et al. First-line nivolumab (anti-PD-1; BMS-936558,ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes withPD-L1 status. Program and abstracts from the 2014 ASCO, Abstract 8024.
44. Charen, AS, Makarov V, Merghoub, et al. The neoantigen landscape underlying clinical responseto ipilimumab.ASCO, Abstract 3003.
45. Reck M, Bondarenko I, Luft, A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin asfirst-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, doubleblind, multicenter phase 2 trial. Ann Oncol. 2013 Jan;24(1):75-83. [PubMed] [CrossRef]
46. Guo Z, Wang X, Cheng D, Xia Z, Luan M, Zhang S. PD-1 blockade and OX40 triggering synergistically protectsagainst tumor growth in a murine model of ovarian cancer. PLoS One. 2014 Feb;9(2):e89350. [PubMed] [CrossRef]
47. Topalian SL, Hodi FS, Brahmer JR. Safety, activity, and immune correlates of anti-PD-1 antibodyin cancer. N Engl J Med. 2012 Jun;366(26):2443-2454. [PubMed] [CrossRef]
48. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patientswith metastatic castration-resistant prostate cancer that had progressed after docetaxelchemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jun;15(7):700-712. [PubMed] [CrossRef]
49. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. Program and abstracts from the 2014 ASCO, Abstract 5009.
50. Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteriafor tumor immunotherapy? Clin Cancer Res. 2009 Dec;15(23):7116-7118. [PubMed] [CrossRef]
51. Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemictreatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009 Aug;58(8):1297-1306. [PubMed] [CrossRef]
52. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity insolid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec;15(23):7412-7420. [PubMed] [CrossRef]
53. Harvey RD. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther. 2014 Aug;96(2):214-223. [PubMed] [CrossRef]
54. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment withpembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparisoncohort of a phase 1 trial. Lancet. 2014 Sep;384(9948):1109-1117. [PubMed] [CrossRef]
55. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable remission, and long-term safety inpatients with advanced melanoma receiving nivolumab. J ClinOncol. 2014 Apr;32(10):1020-1030. [PubMed] [CrossRef]
56. Ipilimumab adverse reaction management guide. Available at: https://www.hcp.yervoy.com/pages/rems.aspx
57. ClinicalTrials.gov. Phase 1 study of sipuleucel-T and ipilimumab in combination for advancedprostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01832870
58. Clinical Trials. gov. A randomized phase 2 trial of immediate vs. delayed anti-CTLA4 blockadefollowing sipuleucel-T treatment for prostate cancer immunotherapy. Available at: http://clinicaltrials.gov/ct2/show/NCT01804465
59. Wada S, Harris TJ, Tryggestad E. Combined treatment effects of radiation and immunotherapy:studies in an autochthonous prostate cancer model. Int J Radiat Oncol Biol Phys. 2013 Nov;87(4):769-776. [PubMed] [CrossRef]
60. Weber, JS, Kudchadkar RR, Gibney GT, et al. Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI). Program and abstracts from the 2014 ASCO. Abstract 3009.
61. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, et al. Persistent antigen at vaccination sites induces tumorspecificCD8+ T cell sequestration, dysfunction, and deletion. Nat Med. 2013 Apr;19(4):465-472. [PubMed] [CrossRef]
62. Weber J, Minor D, D’Angelo S, et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice of chemotherapy in patients withadvanced melanoma after prior anti-CTLA-4 therapy. Program and abstracts from the 2014 ESMO. Abstract LBA3.
63. Hammers HJ, Plimack ER, Infante JR, et al. Phase I study of nivolumab in combination withipilimumab in metastatic renal cell carcinoma (mRCC). Program and abstracts from the 2014ASCO. Abstract 4504.
64. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma (mRCC):results of a randomized, dose-ranging phase II trial. Program and abstracts from the ASCO. Abstract 5009.
65. Slovin S, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy inmetastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/IIstudy. Ann Oncol. 2013 Jul;24(7):1813-1821. [PubMed] [CrossRef]
66. Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen HR, et al. Radiotherapy augments the immune response toprostate cancer in a time-dependent manner. Prostate. 2008 Sep;68(12):1319-1329. [PubMed] [CrossRef]
67. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, et al. Irradiation of tumor cells up-regulates Fas andenhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 2003 Jun;170(12):6338-6347. [PubMed]
68. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in apatient with melanoma. N Engl J Med. 2012 Mar;366(10):925-931. [PubMed] [CrossRef]
69. Weber JS, O’Day S, Urba W, Powderly J, ;Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008 Dec;26(36):5950-5956. [PubMed] [CrossRef]
70. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatinas first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized,double-blind, multicenter phase II study. J Clin Oncol. 2012 Jun;30:2046-2054. [PubMed] [CrossRef]
71. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreatedadvanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010 Feb;11(2):155-164. [PubMed] [CrossRef]
72. Beer TM, Logothetis C, Sharma P, et al. CA184-095: a randomized, double-blind, phase III trial tocompare the efficacy of ipilimumab versus placebo in asymptomatic or minimally symptomaticpatients (pts) with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC).Program and abstracts from the 2012 ASCO. Abstract TPS4691.
73. Joseph RW, Elassaiss-Schapp J, Wolchok JD, et al. Baseline tumor size as an independentprognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. Program and abstracts of the 2014 ASCO. Abstract 3015.
74. ClinicalTrials.gov. A randomized, double-blind, phase 3 efficacy trial of PROSTVAC-V/F +/- GMCSFin men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostatecancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01322490
75. Fizazi K, Drake C, Kwon E, et al. Updated overall survival (OS) from the phase 3 trial, CA184-043: Ipilimumab (Ipi) vs placebo (Pbo) in patients with post-docetaxel metastatic castrationresistantprostate cancer (mCRPC). Program and abstracts from the 2014 ESMO. Abstract 763PD.
76. Schadendorf D, Hodi FS, Roberts C, et al. Pooled analysis of long-term survival data from phaseII and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma.Program and abstracts from the 2013 European Cancer Congress. Abstract LBA24
77. Grosso J, Horak CE, Inzunza D, et al. Association of tumor PD-L1 expression and immunebiomarkers with clinical activity in patients (pts) with advanced solid tumors treated withnivolumab (anti-PD-1; BMS-936558; ONO-4538). Program and abstracts from the 2013 ASCO. Abstract 3016.
78. Sznol M, Kluger HM, Callahan MK, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). Program and abstracts from the 2014ASCO.Abstract LBA9003.
79. Kefford R, Ribas A, Hamid O, et al. Clinical efficacy and correlation with tumor PD-L1 expressionin patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.Program and abstracts from the 2014 ASCO. Abstract 3005.
80. Graff JN, Drake CG, Beer TM. Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research. Urology. 2013 Feb;81(2):381-383. [PubMed] [CrossRef]
81. Graff JN, Puri S, Bifulco CB, Fox BA, Beer TM. Sustained complete response to CTLA-4blockade in a patient with metastatic, castration-resistant prostate cancer. Cancer Immunol Res.2014 May;2(5):399-403. [PubMed] [CrossRef]
82. Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd, et al. Randomized trial of short- versus long-courseradiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005 Jun;97(11):798-804. [PubMed]
83. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiationtherapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2012 Jan;2:215. [PubMed] [CrossRef]
84. Patnaik A, Kang SP, Tolcher AW, et al. Phase I study of MK-3475 (anti-PD-1 monoclonalantibody) in patients with advanced solid tumors. Program and abstracts from the 2012 ASCO. Abstract 2512.
85. Weber JS, Yu B, Hall D, et al. Pharmacodynamic and predictive markers of ipilimumab onmelanoma patients’ T-cells. Program and abstracts from the 2011 Annual Meeting of theAmerican Society of Clinical Oncology. June 3-6, 2011; Chicago, Illinois. Abstract 2503.
86. Clinical Trials.gov. A randomized phase 3 open label study of nivolumab versus bevacizumab anda safety study of nivolumab or nivolumab in combination with ipilimumab in adult subjects withrecurrent glioblastoma (GBM). Available at: http://www.clinicaltrials.gov/ct2/show/NCT02017717
87. Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M. Challenges in immunotherapy presented bythe glioblastoma multiforme microenvironment. Clin Dev Immunol. 2011; 2011:732413. [PubMed] [CrossRef]
88. Pachter JS, De Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in thecentral nervous system. J Neuropath Exper Neurol. 2003 Jun;62(6):593-604. [PubMed]
89. Fabry Z, Raine CS, Hart MN. Nervous tissue as an immune compartment: the dialect of theimmune response in the CNS. Immunol Today. 1994 May;15(5):218-224. [PubMed] [CrossRef]
90. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, et al. Durable cancer regression off-treatment and effectivereinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013 Jan;19(2):462-468. [PubMed] [CrossRef]
91. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J.. Hepatotoxicity with combination of vemurafenib andipilimumab. N Engl J Med. 2013 Apr;368(14):1365-1366. [PubMed] [CrossRef].
Received: 26 July 2015
Published online: 16 November 2015